| Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice H Tasfaout, S Buono, S Guo, C Kretz, N Messaddeq, S Booten, ... Nature Communications 8 (1), 15661, 2017 | 91 | 2017 |
| Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation BS Cowling, I Prokic, H Tasfaout, A Rabai, F Humbert, B Rinaldi, AS Nicot, ... The Journal of clinical investigation 127 (12), 4477-4487, 2017 | 79 | 2017 |
| Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy S Buono, JA Ross, H Tasfaout, Y Levy, C Kretz, L Tayefeh, J Matson, ... Proceedings of the National Academy of Sciences 115 (43), 11066-11071, 2018 | 59 | 2018 |
| Single intramuscular injection of AAV-shRNA reduces DNM2 and prevents myotubular myopathy in mice H Tasfaout, VM Lionello, C Kretz, P Koebel, N Messaddeq, D Bitz, ... Molecular Therapy 26 (4), 1082-1092, 2018 | 49 | 2018 |
| Centronuclear myopathies under attack: a plethora of therapeutic targets H Tasfaout, BS Cowling, J Laporte Journal of neuromuscular diseases 5 (4), 387-406, 2018 | 42 | 2018 |
| Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion N Vasli, E Harris, J Karamchandani, E Bareke, J Majewski, NB Romero, ... Brain 140 (1), 37-48, 2017 | 40 | 2017 |
| Differential physiological roles for BIN1 isoforms in skeletal muscle development, function and regeneration I Prokic, BS Cowling, C Kutchukian, C Kretz, H Tasfaout, V Gache, ... Disease models & mechanisms 13 (11), dmm044354, 2020 | 23 | 2020 |
| Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles NE Bengtsson, H Tasfaout, SD Hauschka, JS Chamberlain Molecular therapy 29 (3), 1070-1085, 2021 | 19 | 2021 |
| rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy JA Ross, H Tasfaout, Y Levy, J Morgan, BS Cowling, J Laporte, E Zanoteli, ... Acta neuropathologica communications 8, 1-16, 2020 | 14 | 2020 |
| Dynamin 2 inhibitor for the treatment of centronuclear myopathies J Laporte, B Cowling, H Tasfaout US Patent 10,647,986, 2020 | 9 | 2020 |
| Dynamin 2 inhibitor for the treatment of centronuclear myopathies J Laporte, B Cowling, H Tasfaout US Patent 11,499,155, 2022 | 1 | 2022 |
| Split intein-mediated protein trans-splicing to express large dystrophins H Tasfaout, CL Halbert, TS McMillen, JM Allen, TR Reyes, GV Flint, ... Nature, 1-9, 2024 | | 2024 |
| Dynamin 2 inhibitor for the treatment of centronuclear myopathies J Laporte, B Cowling, H Tasfaout US Patent App. 18/053,771, 2023 | | 2023 |
| Development of New Micro-Dystrophins with Enhanced Cardiac Functionality H Tasfaout, JM Allen, CL Halbert, JS Chamberlain MOLECULAR THERAPY 30 (4), 501-501, 2022 | | 2022 |
| CONGENITAL MYOPATHIES (CNM): P. 144Targeting dynamin 2 rescues the three main forms of centronuclear myopathies H Tasfaout, S Buono, I Prokic, J Ross, C Kretz, S Guo, P Koebel, B Monia, ... Neuromuscular Disorders 28, S72-S73, 2018 | | 2018 |
| Physiopathologie et validation préclinique dans les myopathies centronucleaires H Tasfaout Université de Strasbourg, 2017 | | 2017 |
| ASO-mediated Dnm2 knockdown prevents and reverts Myotubular myopathy in vivo in mice H Tasfaout, S Buono, S Guo, C Kretz, B Monia, J Laporte, BS Cowling HUMAN GENE THERAPY 27 (11), A44-A44, 2016 | | 2016 |
| ASO-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice H Tasfaout, S Buono, S Guo, C Kretz, B Monia, B Cowling, J Laporte Neuromuscular Disorders 26, S209-S210, 2016 | | 2016 |
| GO 22: Reducing dynamin 2 rescues centronuclear myopathy BS Cowling, T Chevremont, I Prokic, H Tasfaout, C Kretz, A Ferry, ... Neuromuscular Disorders 24 (9), 921-922, 2014 | | 2014 |
